SYK:NYSEStryker Corporation Analysis
Data as of 2026-09-08 - not real-time
$303.13
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Stryker Corporation is priced at $303.13, and its moving averages give no clean directional read — the structure is neutral. Across the trailing 30 sessions it lost 8.2%. Momentum indicators put RSI at 34.1 (approaching oversold) with MACD reading bearish. Price has been bracketed by support at $302.51 and resistance at $349.77.
On valuation the read is fair — earnings multiple of 31.4 versus a 30.6 sector average, in line with the peer group. Consensus targets land 26.3% above where the shares trade now. Revenue is growing at 9.4% on a 14.4% profit margin. The 1.16% dividend yield looks covered by current payout levels.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 35.4%, a beta of 0.13 and a maximum drawdown of 28.1%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
On valuation the read is fair — earnings multiple of 31.4 versus a 30.6 sector average, in line with the peer group. Consensus targets land 26.3% above where the shares trade now. Revenue is growing at 9.4% on a 14.4% profit margin. The 1.16% dividend yield looks covered by current payout levels.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 35.4%, a beta of 0.13 and a maximum drawdown of 28.1%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 3 out of 10.
Top Market Events
Medical technology company Stryker NYSE:SYK in Q2 CY2026, with sales up 9.Stryker Corp SYK delivers robust Q2 2026 results with 17.Stryker bounced back from a March cyber attack to post its fifth straight earnings beat, with adjusted EPS of $3.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Trading below the 200-day average of 338.45
- MACD momentum is negative
- 30-day price change of -8.2%
Medium Term
1–3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 31.4 versus sector average of 30.6
- Trading below the 200-day average of 338.45
- Analyst targets imply +26.3% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 31.4 versus sector average of 30.6
- Analyst targets imply +26.3% versus the current price
- Return on equity of 16.5%
Key Metrics & Analysis
Financial Health
Revenue Growth9.40%
Profit Margin14.43%
P/E Ratio31.4
ROE16.51%
ROA8.16%
Debt/Equity64.39
P/B Ratio4.8
Op. Cash Flow$5.5B
Free Cash Flow$4.1B
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI34.1
Support$302.51
Resistance$349.77
MA 20$329.35
MA 50$328.91
MA 200$338.45
MACDBearish
VolumeStable
Fear & Greed Index93.64
Valuation
Fair Value$170.26
Target Price$382.72
Upside/Downside26.26%
GradeFair
TypeGrowth
Dividend Yield1.16%
Risk Assessment
Beta0.13
Volatility35.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.